Managers / Q2 2021 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $385M in U.S.-listed holdings across 15 positions for Q2 2021.
Its largest position, Dicerna Pharmaceuticals, represents 17.6% of the portfolio.
Compared with Q1 2021, the fund opened 0 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 81.5% · $314M
- Other · 13.0% · $50M
- ADR · 5.5% · $21M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| FDMT4D MOLECULAR THERAPEUTICS IN | ADDED | +644.5K | 945.4K | +$10M | $23M |
| SPYSPDR S&P 500 ETF TR | SOLD OUT | −300.0K | 0 | −$119M | $0 |
| XBISPDR S&P BIOTECH ETF TR | SOLD OUT | −500.0K | 0 | −$68M | $0 |
| HARPOON THERAPEUTICS INC | TRIMMED | −841.5K | 712.7K | −$23M | $10M |
| AMRYT PHARMA PLC | ADDED | +340.0K | 1.14M | +$3M | $14M |
| GALAPAGOS NV | ADDED | +25.6K | 142.3K | +$808,000 | $10M |
| QUREUNIQURE NV | ADDED | +202.1K | 1.16M | +$3M | $36M |
| PIERIS PHARMACEUTICALS INC | TRIMMED | −479.0K | 3.20M | +$3M | $12M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | DICERNA PHARMACEUTICALS INC | COM | 17.58% | $68M | 1.81M |
| 2 | SPROSPERO THERAPEUTICS INChistory → | COM | 13.89% | $53M | 3.83M |
| 3 | BLUEPRINT MEDICINES CORP | COM | 10.25% | $39M | 448.5K |
| 4 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 9.32% | $36M | 432.9K |
| 5 | QUREUNIQURE NVhistory → | SHS | 9.26% | $36M | 1.16M |
| 6 | MAGENTA THERAPEUTICS INC | COM | 6.83% | $26M | 2.69M |
| 7 | NGM BIOPHARMACEUTICALS INC | COM | 6.12% | $24M | 1.19M |
| 8 | RGNXREGENXBIO INChistory → | COM | 6.01% | $23M | 595.4K |
| 9 | FDMT4D MOLECULAR THERAPEUTICS INhistory → | COM | 5.92% | $23M | 945.4K |
| 10 | AMRYT PHARMA PLC | SPONSORED ADS | 3.59% | $14M | 1.14M |
| 11 | PIERIS PHARMACEUTICALS INC | COM | 3.18% | $12M | 3.20M |
| 12 | HARPOON THERAPEUTICS INC | COM | 2.57% | $10M | 712.7K |
| 13 | GALAPAGOS NV | SPON ADR | 2.55% | $10M | 142.3K |
| 14 | ARGXARGENX SEhistory → | SPONSORED ADR | 1.66% | $6M | 21.2K |
| 15 | GMABGENMAB A/Shistory → | SPONSORED ADS | 1.27% | $5M | 120.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.